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Abstract: 
 
Background: Human cytomegalovirus (HCMV) infects ~50% of adults in the United States. 
HCMV infections may cause vascular inflammation leading to cardiovascular disease, but the 
existing evidence is inconsistent. Objective: We investigated demographic predictors of HCMV 
infection and explored associations between HCMV infection status, the intensity of anti-HCMV 
Immunoglobulin G (IgG) antibody response, and biomarkers of inflammation and endothelial 
function which are known predictors of cardiovascular disease. Methods: We conducted a cross-
sectional study of 694 adults residing in the Raleigh-Durham-Chapel Hill, NC metropolitan area. 
Serum samples were tested for IgG antibody response to HCMV, and for biomarkers of vascular 
injury including soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell 
adhesion molecule 1 (sVCAM-1), C-reactive protein (CRP), and serum amyloid A (SAA). 
Associations between HCMV and biomarker levels were analyzed using two approaches with 
HCMV serostatus modeled as a binary variable and as an ordinal variable with five categories 
comprised of seronegative individuals and quartiles of anti-HCMV antibody responses in 
seropositive individuals. Results: HCMV seroprevalence in the study population was 56%. 
Increased body mass index, increased age, female gender, racial/ethnic minority status, and 
current smoking were significantly associated with HCMV seropositivity in a multivariate 
regression analysis. HCMV seropositivity was also associated with 9% (95% confidence interval 
4–15%) and 20% (0.3–44%) increases in median levels of sICAM-1 and CRP, respectively, after 
adjusting for covariates. The association between HCMV seropositivity and median levels of 
sVCAM-1 and SAA were positive but not statistically significant. Significant positive 
associations were observed between the intensity of anti-HCMV IgG responses and levels of 
sICAM-1 and sVCAM-1 (p-values 0.0008 and 0.04 for linear trend, respectively). To our 
knowledge, this is the first epidemiological study to show a relationship between anti-HCMV 
IgG responses and vascular injury biomarkers sICAM-1 and sVCAM-1 in the general 
population. Conclusion: HCMV infections are associated with vascular injury and inflammation 
biomarkers in adult residents of North Carolina. 
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Background: Human cytomegalovirus (HCMV) infects ∼50% of adults in the
United States. HCMV infections may cause vascular inflammation leading to
cardiovascular disease, but the existing evidence is inconsistent.
Objective: We investigated demographic predictors of HCMV infection and explored
associations between HCMV infection status, the intensity of anti-HCMV Immunoglobulin
G (IgG) antibody response, and biomarkers of inflammation and endothelial function
which are known predictors of cardiovascular disease.
Methods: We conducted a cross-sectional study of 694 adults residing in the
Raleigh-Durham-Chapel Hill, NC metropolitan area. Serum samples were tested for IgG
antibody response to HCMV, and for biomarkers of vascular injury including soluble
intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule
1 (sVCAM-1), C-reactive protein (CRP), and serum amyloid A (SAA). Associations
between HCMV and biomarker levels were analyzed using two approaches with HCMV
serostatus modeled as a binary variable and as an ordinal variable with five categories
comprised of seronegative individuals and quartiles of anti-HCMV antibody responses in
seropositive individuals.
Results: HCMV seroprevalence in the study population was 56%. Increased body mass
index, increased age, female gender, racial/ethnic minority status, and current smoking
were significantly associated with HCMV seropositivity in a multivariate regression
analysis. HCMV seropositivity was also associated with 9% (95% confidence interval
4–15%) and 20% (0.3–44%) increases inmedian levels of sICAM-1 andCRP, respectively,
after adjusting for covariates. The association between HCMV seropositivity and median
levels of sVCAM-1 and SAA were positive but not statistically significant. Significant
positive associations were observed between the intensity of anti-HCMV IgG responses
and levels of sICAM-1 and sVCAM-1 (p-values 0.0008 and 0.04 for linear trend,
respectively). To our knowledge, this is the first epidemiological study to show a
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relationship between anti-HCMV IgG responses and vascular injury biomarkers sICAM-1
and sVCAM-1 in the general population.
Conclusion: HCMV infections are associated with vascular injury and inflammation
biomarkers in adult residents of North Carolina.
Keywords: cardiovascular disease, cytomegalovirus—HCMV, serum amyloid A, vascular injury, biomarkers,
intercellular adhesion molecular-1 (ICAM-1), C-reactive protein, vascular cell adhesion molecule-1 (VCAM-1)
INTRODUCTION
Human cytomegalovirus (HCMV) is a member of the herpes
virus family. The virus can be transmitted through person-to-
person contacts involving exchange of infected bodily fluids such
as blood, saliva, breast milk, urine, oropharyngeal secretions,
cervical, vaginal secretions, and seminal fluid; sexual contact
is a frequent mode of transmission (Cannon et al., 2010).
HCMV causes a long-term latent infection with periodic flare-
ups. In a new HCMV infection, immunoglobulin M (IgM) is
produced for ∼3–6 months, after which HCMV-specific IgM
can no longer be detected in serum (Prince and Lapé-Nixon,
2014). During this 3–6-month period, the immunoglobulin G
(IgG) response is established and remains high throughout
the life-long latency of an HCMV infection. Serum IgG tests
are widely used to determine HCMV infection status. Anti-
HCMV IgG response increases during reactivation or reinfection
of HCMV (Mehta et al., 2000; Carlson et al., 2010; Prince
and Lapé-Nixon, 2014). The IgG seroprevalence of HCMV in
the US was 50.4 % between 1999 and 2004 according to the
National Health and Nutrition Examination Survey (NHANES)
(Bate et al., 2010).
Infection with HCMV is an important public health concern
(Schleiss, 2008). It causes ∼30,000 (0.7%) congenital infections
annually in the US resulting in hearing loss, speech and
developmental disabilities, or death for infected children (Ross
and Boppana, 2004; Dollard et al., 2007; Martin et al.,
2010). In adults with non-compromised immune systems,
HCMV infection may occur without symptoms although
some individuals may have transient mild mononucleosis-like
symptoms (Lancini et al., 2014). Chronic HCMV infections
have been associated with increased risks of cardiovascular
disease (CVD), immune dysfunction, frailty, and depression
(Simanek et al., 2014; Collins-Mcmillen et al., 2018). A proposed
mechanism for the development of CVD as a result of
HCMV infection is the increased conversion of prothrombin
to thrombin, a clot forming agent, either directly or indirectly
through increased inflammation (Popović et al., 2012). Previous
in vivo and in vitro studies of CVD development due to HCMV
infection have produced mixed results. High prevalence of
HCMV viruses has been demonstrated in carotid atherosclerotic
plaques (Yaiw et al., 2013). Some studies have also demonstrated
positive associations between HCMV infection and various
biomarkers of inflammation, endothelial function and vascular
injury, such as C-reactive protein (CRP), soluble intercellular
adhesion molecule 1 (sICAM-1), and soluble vascular cell
adhesionmolecule 1 (sVCAM-1). Several epidemiological studies
have linked HCMV seropositivity with increased levels of CRP
(Fateh-Moghadam et al., 2003; Betjes et al., 2007; Simanek
et al., 2011); however, this association was not observed in
two other studies, potentially due to the non-specific nature of
inflammatory biomarker CRP (Simanek et al., 2014; Terrazzini
et al., 2014). Three small (>100 participants) epidemiologic
studies found associations between anti-HCMV IgG responses
and increased levels of sICAM-1 and sVCAM-1 in serum samples
in renal transplant patients and symptomatic individuals with
primary HCMV infections, but not in asymptomatic healthy
individuals (Nordoy et al., 2000; Eriksson et al., 2001; Lee
et al., 2019). In-vitro experiments demonstrated that cellular
adhesion molecules sVCAM-1 and sICAM-1 are released when
endothelial cells are infected with HCMV (Popović et al.,
2012). Meta-analysis of prospective studies demonstrated that
HCMV infections were associated with an increased risk of CVD
although some cohort studies included in this analysis detected
no such association (Haider et al., 2002).
The objective of this study was to assess if HCMV infection
affects four selected biomarkers of inflammation and endothelial
function which are known predictors of cardiovascular morbidity
and mortality: CRP, serum amyloid A (SAA), sVCAM-1, and
sICAM-1. CRP and SAA are markers of acute inflammation.
Chronically elevated CRP is linked with coronary artery disease
however, elevated serum levels of CRP or SAA can also
indicate other health conditions such as cancer (Zakynthinos
and Pappa, 2009; Kaptoge et al., 2012; Baumann et al., 2017).
VCAM-1 and ICAM-1 are biomarkers of endothelial function.
These molecules are released into circulation by vascular
endothelial cells in response to inflammation. Their useful
functions include stable mediation of leukocyte adherence to
the vascular endothelium and transmigration. However, elevated
concentrations of VCAM-1 and ICAM-1 are linked with the
development of atherosclerosis (Blankenberg et al., 2003; Galkina
and Ley, 2007; Zakynthinos and Pappa, 2009).
MATERIALS AND METHODS
Study Population
The ethical considerations of this study were reviewed and
approved by the University of North Carolina Institutional
Review Board (UNC IRB ref. # 12-2600). All participants
provided written consent prior to data collection.
This study was comprised of two subsets of a cross sectional
study of 703 adults (>18 years of age) in the Raleigh-Durham-
Chapel Hill metropolitan area in North Carolina in 2013. The
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first sub-set was a convenience sample study (n1 = 352) recruited
by the United States Environmental Protection Agency (US EPA)
through local advertising (hereon referred to as US EPA subset).
The second subset of individuals (n2 = 351) was recruited for the
Sample Collection Registry for Quality Control of Biological and
Environmental Specimens and Assay Development and Testing
study protocol number 10-E-0063, ClinicalTrials.gov identifier
NCT01087307 at the National Institute of Environmental Health
Sciences (NIEHS), Research Triangle Park, NC (hereon referred
to as NIEHS subset).
Serum samples and questionnaire data from the US EPA
subset were collected as part of a cross sectional study of
chronic infections conducted in 2013 at the US EPA Human
Studies Facility in Chapel Hill, NC. For the NIEHS subset,
recruitment and data collection were conducted at the NIEHS
facility (Research Triangle Park, NC) in 2013. Aliquots of serum
samples and questionnaire data from the NIEHS subset were
shared with the US EPA. Collected serum samples were archived
at−80◦C until they were assayed for this study between late 2016
and early 2017.
The present study involved laboratory analysis of both subsets
of samples for anti-HCMV IgG and analysis of biomarkers of
vascular injury in the NIEHS subset. Samples from the US EPA
subset have previously been analyzed using the same methods
as the present study for multiple biomarkers of health including
biomarkers of inflammation and endothelial function/vascular
injury under research projects on the health effects of urban green
spaces (Egorov et al., 2017, 2018).
Questionnaire Data and Health
Examinations
Participants reported their demographic information (age,
gender, race, ethnicity) and smoking history. However, only the
US EPA survey included information on education level. None
of the surveys collected data on income or assets. There were
differences in smoking history questions between NIEHS and US
EPA surveys: “current smoker” was defined as a participant who
had smoked in the past 24 h (NIEHS) or who reported being
a current smoker (US EPA). For the purpose of the analysis in
this study, smoking data from both surveys were combined into
a single binary variable (smoker vs. non-smoker). Height and
weight data were measured by clinical staff at the US EPA or
NIEHS facilities. BodyMass Index (BMI) was calculated using the
measured height andweight of participants and categorized using
the World Health Organization (WHO) standard definitions
for BMI categories: underweight, normal, overweight and obese
(WHO, 2000).
Laboratory Analysis
Serum samples were tested for IgG antibody response to HCMV
using a commercially available ELISA kit (cat# ab108724, Abcam,
Cambridge, MA) following manufacturer’s instructions. Serum
samples were diluted 1:100 in the manufacturer provided sample
diluent prior to being assayed. Twenty percent of samples
were assayed in replicate on the same or different plates.
The acceptable level of the coefficient of variation was set
below 20%; results not conforming with this requirement were
excluded from statistical analysis. Blank corrected optical density
(OD) values were divided by the plate specific cutoff value.
Seropositive samples were defined as those with HCMV ratio to
plate specific cutoff value >1.1 according to the manufacturer’s
instruction. Samples with inconclusive results (HCMV ratio to
plate specific cutoff value 0.9–1.1) were retested. For a single
sample that remained inconclusive after several retests the result
was dichotomized using the average HCMV ratio of 1.0 as
a cutoff.
Serum CRP, SAA, sVCAM-1, and sICAM-1
levels were analyzed using a commercially available
electrochemiluminescence Meso Scale Discovery (MSD)
quadruplex Vascular Injury Panel 2 microplate assay (cat#
K15198D, MSD, Rockville, MD) following manufacturer’s
instructions. Serum samples were centrifuged at 2000 × g for
3min and then diluted 1:1,000 in the assay diluent prior to
analysis. Twenty percent of samples were assayed in replicate on
the same or different plates. The acceptable level of the coefficient
of variation was set below 20%; results not conforming with this
requirement were excluded from statistical analysis. Responses
were measured using an MSD QuickPlex SQ 120 instrument.
Concentrations of the analytes were estimated from four-
parameter logistic regression models fitted to serially diluted
standards, as per manufacturer’s instructions.
Statistical Data Analysis
R (version 3.5.1) and SAS (version 9.4) statistical analysis
software packages were used to analyze the survey and
assay data. Shapiro-Wilks test for normality and quantile-
quantile (Q-Q) plots were used to determine if logarithmic
transformations were warranted. All four biomarkers of vascular
injury (sICAM-1, sVCAM-1, CRP, and SAA), as well as
BMI data were log-transformed to satisfy assumptions of
normality. Race and ethnicity data were combined and
dichotomized as non-Hispanic whites vs. all others. Race
and ethnicity data were dichotomized this way because
representation from other race categories in this study was
not sufficient to make statistical comparisons. Missing values
for covariates were imputed using the SAS procedure mi for
arbitrary missing data based on the multivariate discriminant
function method.
Next, a multivariate predictive logistic regression model
was developed for HCMV seropositivity. Covariates that were
significant predictors (p < 0.05) of HCMV seropositivity in
this model (age, BMI, gender, race/ethnicity, smoking status)
were also incorporated in subsequent regression models to
analyze associations between HCMV serostatus and vascular
injury biomarkers.
The association between HCMV serostatus and levels
of vascular injury biomarkers were investigated using
linear regression models adjusted for covariates (SAS
procedure genmod). Two alternative approaches were
used. First, a binary variable for HCMV serostatus was
used to assess the effects of seropositivity (Model 1).
Second, anti-HCMV IgG antibody data were categorized as
seronegative (reference category); or as 1st, 2nd, 3rd, or 4th
quartiles of antibody responses in seropositive individuals
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in order to investigate whether there was an association
between the intensity of anti-HCMV IgG responses and
the levels of vascular injury biomarkers (Model 2). All
results were expressed as percent changes in the median
biomarker values.
Additional analysis under the second approach was
conducted using the SAS procedure glm with the contrast
statement in order to test for a linear trend in the effect
of the intensity of anti-HCMV IgG antibody response on
vascular injury biomarkers. This analysis was conducted
using the ordinal variable for anti-HCMV IgG response as
described above and assuming equal distances between all
adjacent categories.
RESULTS
Serum samples from 694 of 703 study participants (99%) were
tested for anti-HCMV IgG response and all four biomarkers
of vascular injury. Nine samples could not be analyzed due
to low sample volumes. Seroprevalence of HCMV was 56%
(Table 1). All samples retested on different plate lots produced
consistent results. The age of participants ranged from 18 to 85
years. Almost two-thirds (62%) of participants were women. A
majority of participants (51%) were non-Hispanic whites while
16% of participants declined to report their race. Almost a quarter
(23%) of participants reported a habit of smoking. Almost two-
thirds of participants (66%) were overweight or obese (BMI
TABLE 1 | Descriptive statistics for the study population.
Factor Level N % HCMV seropositive % seropositive Chi-Square test p-value
All 694 100% 391 56% N/A
Age category
(years) 18–29 206 30% 91 44%
30–39 138 20% 82 59%
40–49 130 19% 87 67%
50–59 152 22% 92 61%
60–85 68 10% 39 57% 0.0005
BMI
(kg/m2 ) Underweight (<18.5) 7 1% 3 43%
Normal Weight (18.5–24.9) 226 33% 107 47%
Overweight (25.0–29.9) 209 30% 116 56%
Obese (≥30) 252 36% 165 65% <0.0001*
Gender
Male 264 38% 128 48%
Female 430 62% 263 61% 0.001
Race
White 376 54% 153 40.7%
Black or African American 187 27% 139 74.3%
American Indian or Alaska Native 2 0.3% 1 50.0%
Asian or Pacific Islander 9 1.3% 4 44.4%
Other 17 2.4% 13 76.5% <0.0001**
Not reported 103 15% 81 78.6%
Ethnicity
Non-Hispanic 558 80% 287 51.4%
Hispanic 34 5% 25 73.5% 0.01
Not reported 102 15% 79 77.5%
Race/ethnicity
Non-Hispanic whites 353 51% 138 39%
Other 231 33% 168 73% <0.0001
Not reported 110 16% 85 77%
Smoking habits
Non-smoker 531 77% 273 51%
Smoker 159 23% 115 72% <0.0001
Not reported 4 0.6% 3 75%
N/A, not applicable.
*Cochran-Armitage trend test.
**Non-Hispanic White vs. all other races/ethnicities.
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≥ 25.0 kg/m2). Age, BMI, gender, smoking, and race/ethnicity
status were significantly associated with HCMV seropositivity in
exploratory univariate analysis (Table 1).
For regression analysis, missing race/ethnicity data (n = 110)
and missing smoking data (n = 4) were imputed as described
in the Methods section. Results of a multivariate predictive
regression analysis for HCMV seropositivity demonstrated that
increased age, female gender, racial/ethnic minority status,
smoking, and greater BMI were significant predictors of HCMV
seropositivity (Table 2). Specifically, a 10-year increase in age
was associated with 1.25 (95% CI 1.11–1.41) adjusted odds ratio
(aOR) of seropositivity. Women had 2.06 (1.47–2.89) aOR of
being seropositive compared tomen. Non-white and/or Hispanic
individuals had 2.90 (2.03–4.13) aOR of being seropositive
compared to non-Hispanic whites. Current smokers had 2.32
(1.54–3.51) aOR of seropositivity compared to non-smokers.
TABLE 2 | Effects of demographic predictors on HCMV seropositivity—adjusted
odds ratios (OR) with a 95% confidence interval from a multivariate logistic
regression model.
Predictor Level Adjusted OR (95 % CI)
Age (per 10-year increase) NA 1.25 (1.11, 1.41)
Gender Males Reference
Females 2.06 (1.47, 2.89)
Race/ethnicity non-Hispanic whites Reference
All others 2.90 (2.03, 4.13)
Smoking Non-smoker Reference
Smoker 2.32 (1.54, 3.51)
BMI (per 100% increase) NA 1.72 (1.02, 2.88)
For regression analysis, BMI data were log2-transformed; thus,
the effect estimate is expressed as 1.72 (1.02–2.88) aOR of
seropositivity per doubling of BMI values.
HCMV seropositivity was associated with significantly
increased levels of sICAM-1 and CRP after adjusting for
covariates (Table 3).Median adjusted sICAM-1 andCRP levels in
seropositive individuals were 9.2% (4.5–15%) and 20% (0.3–44%)
higher than in seronegative controls, respectively.
In addition, greater intensity of anti-HCMV IgG antibody
responses was significantly associated with increased levels
sICAM-1 and sVCAM-1 (Table 3). Individuals in the top quartile
of anti-HCMV IgG antibody responses had 16% (8.0–25%) and
7.7% (0.6–15%) higher median levels of sICAM-1 and sVCAM-
1, respectively, compared to seronegative controls. Tests for
linear trend using ordinal data on anti-HCMV IgG responses
produced significant results for both sICAM-1 and sVCAM-1.
Dose-response associations between the intensity of anti-HCMV
IgG antibody response and biomarker level were not observed for
CRP nor SAA.
DISCUSSION
We observed that HCMV seropositivity increased with
greater age and BMI, and was more common among non-
white and/or Hispanic individuals, women and smokers.
Associations between HCMV seropositivity and increased
age, race/ethnicity, and female gender are consistent with
previously published results (Bate et al., 2010; Cannon et al.,
2010; Simanek et al., 2011). Smoking, which is associated with
lower socioeconomic status (Hiscock et al., 2012), has also
been controlled for in previous studies of HCMV and CVD
(Simanek et al., 2011).
TABLE 3 | Multiplicative effect estimates (95% confidence intervals) of HCMV seropositivity or the intensity of anti-HCMV IgG antibody responses on vascular injury
biomarkers. All models were adjusted for age, BMI, smoking status, gender, and race/ethnicity.
Model CMV serostatus,
median value
(range of values)**
sICAM-1 sVCAM-1 CRP SAA
Effect estimate
(% change)
p-value for
trend
Effect estimate
(% change)
p-value for
trend
Effect estimate
(% change)
p-value for
trend
Effect estimate
(% change)
p-value for
trend
1. Seropositivity Negative 0.38
(0.13–1.07)
Reference Reference Reference Reference
Positive all 3.86
(1.10–10.97)
9.2 (4.1, 15) 2.2 (−2.3, 6.9) 20 (0.3, 44) 11 (−7.4, 32)
2. Intensity of
anti-HCMV IgG
response
Negative 0.38
(0.13–1.07)
Reference Reference Reference Reference
Positive 1st quartile
2.14 (1.10–2.68)
6.9 (−0.3, 15) −0.9 (−7.1, 5.8) 28 (−1.5, 67) 29 (−0.4, 66)
Posit. 2nd quartile
3.26 (2.69–3.86)
8.7 (1.5, 17) 1.9 (−4.5, 8.6) 35 (4.4, 76) −1.8 (−24, 27)
Posit. 3rd quartile
4.40 (3.87–4.86)
6.6 (−0.6, 14) 1.3 (−5.1, 8.2) −3.1 (−26; 26) −2.6 (−25, 26)
Posit. 4th quartile
5.63 (4.90–10.97)
16 (8.0, 25) 0.0008 7.7 (0.6, 15) 0.04 23 (−6.5, 62) 0.7 23 (−5.8, 61) 0.7
**Test values represent the ratio of optical densities of the sample and microplate-specific control.
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Regression models were adjusted for the above socio-
demographic covariates, and two models (previously described)
were used to explore associations between anti-HCMV IgG
responses and levels of vascular injury and inflammation
biomarkers. HCMV-seropositive individuals had significantly
higher levels of sICAM-1 and CRP than seronegative controls.
In addition, significant linear trends were observed between
the intensity of anti-HCMV antibody responses and levels of
sICAM-1 and sVCAM-1, but not levels of CRP. The observed
association between HCMV serostatus and SAA was positive but
not statistically significant, and there was no linear trend for
this biomarker.
Results of this study corroborated previously observed
associations betweenHCMV seropositivity and serumCRP levels
(Fateh-Moghadam et al., 2003; Betjes et al., 2007; Simanek et al.,
2011). To our knowledge, this was the first epidemiological study
in the general population to show associations between anti-
HCMV IgG responses and vascular injury biomarkers sICAM-
1 and sVCAM-1. Previous research has only demonstrated the
effects of HCMV on these cellular adhesion molecules in vitro,
as well as in renal transplant recipients and individuals with
symptomatic primary HCMV infection (Nordoy et al., 2000;
Eriksson et al., 2001; Popović et al., 2012).
VCAM-1 and ICAM-1 play important roles in the vascular
endothelium (Zakynthinos and Pappa, 2009). HCMV has
been detected in endothelial cells (Crough and Khanna,
2009; Terrazzini et al., 2014). It has been proposed that the
disruption of endothelial cells by HCMV triggers induction
of proinflammatory adhesion molecules sICAM-1 and
sVCAM-1, which potentially contributes to atherosclerosis
and atherothrombosis (Popović et al., 2012). Our finding that
elevated HCMV IgG response is associated with increased serum
levels of sICAM-1 and sVCAM-1 provides further support for
this hypothesis.
Previous epidemiological research demonstrated that
exposure to common air pollutants was associated with
increased levels of CRP, sICAM-1 and sVCAM-1 (Bind
et al., 2012). Air pollution has been shown to cause adverse
impacts on the cardiovascular system including endothelial
dysfunction, atherosclerosis and thrombosis leading to increased
risks of cardiovascular morbidity and mortality (An et al.,
2018; Tibuakuu et al., 2018). Therefore, the associations
between HCMV and vascular injury biomarkers observed
in this study suggest that HCMV infection may increase
susceptibility to detrimental health effects of air pollution. Our
results suggest that in future investigations of the relationship
between air pollution and CVD risk, it would be beneficial to
control for HCMV serostatus due to the high prevalence of
HCMV infection.
This cross-sectional study involved collecting information
on common socio-demographic confounders (variables that are
associated with both HCMV and vascular injury biomarkers)
which have been controlled for in previous studies of HCMV
infections. However, unaccounted confounders might have
biased the observed associations between HCMV seropositivity
and increased levels of vascular injury biomarkers. Although
our regression analysis adjusted for age (a common predictor of
chronic herpesvirus infections) and other demographic factors,
we cannot completely rule out that the observed associations
were partially confounded by other herpesviruses, such as
Epstein-Barr virus (EBV).
Anti-HCMV IgM serum antibodies were not measured in
the present study due to the low likelihood of detecting active
primary HCMV infections in this cross-sectional sample of adult
US residents. Previous research demonstrated that the incidence
rate in the US population ages 12–49 was∼1.6 infections per 100
susceptible person-years in 1988–1994 (Colugnati et al., 2007).
Therefore, we are unable to conclude that all anti-HCMV IgG
positive results were due to latent infection, even though it was
the most likely stage of infection that the HCMV seropositive
participants were experiencing.
The IgG test kits used in this study had high reported
sensitivity (98%) and specificity (97.5%). Thus, false-positive
responses and false-negative responses were unlikely to have a
substantial impact on the observed associations of anti-HCMV
IgG responses with vascular injury biomarkers.
The strength of our study lies in demonstrating positive
associations between the intensity of anti-HCMV IgG antibody
responses and vascular injury biomarkers sICAM-1 and sVCAM-
1. Arguably, socioeconomic factors, such as income and
education, are less likely to confound these associations.
However, it has been shown that the HCMV reactivation rate
increases with age and is higher in women than in men (van
Boven et al., 2017). While age and gender were controlled for
in regression models in this study, there might be hypothetical
unmeasured behavioral or life-style confounding factors that
affected both the frequency of HCMV reactivation and the levels
of vascular injury biomarkers. Further research which follows
participants over time is warranted in order to confirm an
association between HCMV reactivation and levels of vascular
injury biomarkers, and to elucidate the triggers of HCMV-
related inflammation.
CONCLUSION
We observed associations between HCMV serostatus, intensity
of anti-HCMV IgG responses, and vascular injury biomarkers
sVCAM-1, sICAM-1, and CRP, which are known predictors of
adverse cardiovascular outcomes. These findings suggest that
a HCMV infection may contribute to the development of
atherosclerosis and CVD.
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